Chardan Capital Reaffirms “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS)

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, HC Wainwright dropped their price target on SAB Biotherapeutics from $10.00 to $6.00 and set a buy rating for the company in a report on Tuesday, April 2nd.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $4.29 on Tuesday. SAB Biotherapeutics has a twelve month low of $4.00 and a twelve month high of $11.90. The company’s 50-day moving average price is $4.89 and its two-hundred day moving average price is $3.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Pathstone Family Office LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at about $319,000. Commodore Capital LP bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $1,259,000. Kestra Advisory Services LLC grew its position in SAB Biotherapeutics by 319.0% during the fourth quarter. Kestra Advisory Services LLC now owns 88,000 shares of the company’s stock worth $60,000 after buying an additional 67,000 shares in the last quarter. RTW Investments LP bought a new position in SAB Biotherapeutics during the 4th quarter worth $6,310,000. Finally, Vanguard Group Inc. raised its holdings in SAB Biotherapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 976,938 shares of the company’s stock valued at $615,000 after acquiring an additional 14,200 shares in the last quarter. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.